269 related articles for article (PubMed ID: 33154093)
1. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH
Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093
[TBL] [Abstract][Full Text] [Related]
2. The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression.
Deng M; Tan J; Fan Z; Pham LV; Zhu F; Fang X; Zhao H; Young K; Xu B
Sci Rep; 2023 Oct; 13(1):18554. PubMed ID: 37899423
[TBL] [Abstract][Full Text] [Related]
3. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.
Deng M; Zhang M; Xu-Monette ZY; Pham LV; Tzankov A; Visco C; Fang X; Bhagat G; Zhu F; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Choi WWL; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; van Krieken JH; Piris MA; Winter JN; Hagemeister F; Alinari L; Li Y; Andreeff M; Xu B; Young KH
J Hematol Oncol; 2020 Nov; 13(1):148. PubMed ID: 33148342
[TBL] [Abstract][Full Text] [Related]
4. HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.
Luo C; Yu T; Young KH; Yu L
J Zhejiang Univ Sci B; 2022 Aug; 23(8):666-681. PubMed ID: 35953760
[TBL] [Abstract][Full Text] [Related]
5. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population.
Alduaij W; Collinge B; Ben-Neriah S; Jiang A; Hilton LK; Boyle M; Meissner B; Chong L; Miyata-Takata T; Slack GW; Farinha P; Craig JW; Lytle A; Savage KJ; Villa D; Gerrie AS; Freeman CL; Gascoyne RD; Connors JM; Morin RD; Sehn LH; Mungall AJ; Steidl C; Scott DW
Blood; 2023 May; 141(20):2493-2507. PubMed ID: 36302166
[TBL] [Abstract][Full Text] [Related]
6. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
[TBL] [Abstract][Full Text] [Related]
7. Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit.
Cucco F; Barrans S; Sha C; Clipson A; Crouch S; Dobson R; Chen Z; Thompson JS; Care MA; Cummin T; Caddy J; Liu H; Robinson A; Schuh A; Fitzgibbon J; Painter D; Smith A; Roman E; Tooze R; Burton C; Davies AJ; Westhead DR; Johnson PWM; Du MQ
Leukemia; 2020 May; 34(5):1329-1341. PubMed ID: 31844144
[TBL] [Abstract][Full Text] [Related]
8. Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study.
Hilton LK; Collinge BJ; Ben-Neriah S; Alduaij W; Shaalan H; Weng A; Cruz M; Slack GW; Farinha P; Miyata-Takata T; Boyle M; Meissner B; Cook JR; Ondrejka SL; Ott G; Rosenwald A; Campo E; Amador C; Greiner TC; Raess PW; Song JY; Inghirami GG; Jaffe ES; Weisenburger DD; Chan WC; Beiske K; Fu K; Delabie J; Pittaluga S; Iqbal J; Wright G; Sehn LH; Savage KJ; Mungall AJ; Feldman AL; Staudt LM; Steidl C; Rimsza LM; Morin RD; Scott DW
Blood; 2024 May; ():. PubMed ID: 38701426
[TBL] [Abstract][Full Text] [Related]
9. Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study.
Schiefer AI; Kornauth C; Simonitsch-Klupp I; Skrabs C; Masel EK; Streubel B; Vanura K; Walter K; Migschitz B; Stoiber D; Sexl V; Raderer M; Chott A; da Silva MG; Cabecadas J; Müllauer L; Jäger U; Porpaczy E
Medicine (Baltimore); 2015 Dec; 94(52):e2388. PubMed ID: 26717387
[TBL] [Abstract][Full Text] [Related]
10. The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.
Xia Y; Zhang X
Acta Haematol; 2020; 143(6):520-528. PubMed ID: 32074595
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma.
King RL; Hsi ED; Chan WC; Piris MA; Cook JR; Scott DW; Swerdlow SH
Virchows Arch; 2023 Jan; 482(1):193-205. PubMed ID: 36057749
[TBL] [Abstract][Full Text] [Related]
12. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
13. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
[TBL] [Abstract][Full Text] [Related]
14. Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma.
Meriranta L; Pasanen A; Alkodsi A; Haukka J; Karjalainen-Lindsberg ML; Leppä S
Blood Adv; 2020 Aug; 4(15):3742-3753. PubMed ID: 32780847
[TBL] [Abstract][Full Text] [Related]
15. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
16. Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci.
Adams T; Fuchs D; Shadoan PK; Johnstone L; Lau BM; McGhan L; Anwer F; Al-Kateb H
Cancer Genet; 2018 Apr; 222-223():25-31. PubMed ID: 29666005
[TBL] [Abstract][Full Text] [Related]
17. Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.
Fiskvik I; Beiske K; Delabie J; Yri O; Spetalen S; Karjalainen-Lindsberg ML; Leppä S; Liestøl K; Smeland EB; Holte H
Leuk Lymphoma; 2015 Jun; 56(6):1742-9. PubMed ID: 25284491
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
19. Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?
Gordon MJ; Westin JR
Leuk Lymphoma; 2022 May; 63(5):1034-1044. PubMed ID: 34842019
[TBL] [Abstract][Full Text] [Related]
20. Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL.
Dunleavy K
Curr Treat Options Oncol; 2015 Dec; 16(12):58. PubMed ID: 26634708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
